Original articleFactors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration
Section snippets
Methods
This is a retrospective consecutive case series that was performed in the Jules-Gonin University Eye Hospital in Lausanne, Switzerland. The study was approved by the Swiss Federal Department of Health for retrospective data analysis, and was performed in accordance with the ethical standards of the Declaration of Helsinki.
In this study, we identified a consecutive series of eyes with treatment-naïve active neovascular AMD with PED that were treated with intravitreal anti-VEGF injections between
Results
In this study we assessed 115 eyes of 102 patients. The mean age of the patients was 80 ± 7.8 years, and the male-to-female ratio was 0.44. The angiographic type of CNV at baseline was occult in 61.7% (71 of 115), minimally classic in 19.1% (22 of 115), classic in 4.3% (5 of 115), and retinal angiomatous proliferation (RAP) in 14.8% (17 of 115) of the eyes. At baseline, the mean size of CNV was 3.2 ± 1.5 DA, and the mean size of PED was 1.9 ± 1.1 DA. On ICGA, PEDs were predominantly serous in
Discussion
In this study, we showed that eyes with neovascular AMD with PED showed significant functional and anatomic response to anti-VEGF intravitreal injections of either ranibizumab or aflibercept at month 3. We assessed factors that influence the functional and structural response of PED in neovascular AMD, with a particular focus on the effect of drug type (ie, ranibizumab vs aflibercept). Multivariate analysis showed that change in BCVA was not influenced by drug type but rather by baseline BCVA,
Ali Dirani (MD, MPH, MSc) is currently a clinical retina fellow at Jules-Gonin Eye hospital (University of Lausanne, Switzerland). He is an ophthalmologist graduated from Saint-Joseph University (Beirut, Lebanon). He holds a master degree in public health and a master in biological sciences (genetics and biochemistry). He had published many clinical studies and had participated in many international meetings.
References (36)
- et al.
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Ophthalmology
(2012) - et al.
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies
Ophthalmology
(2014) - et al.
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Am J Ophthalmol
(2013) - et al.
Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration
Ophthalmology
(2014) - et al.
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials
Ophthalmology
(2013) - et al.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Angiogenesis
(2012) - et al.
Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat
Br J Ophthalmol
(1998) - et al.
Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors
Invest Ophthalmol Vis Sci
(1998)
VEGF is major stimulator in model of choroidal neovascularization
Invest Ophthalmol Vis Sci
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment
Arch Ophthalmol
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization
Invest Ophthalmol Vis Sci
Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes
Invest Ophthalmol Vis Sci
Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy
Invest Ophthalmol Vis Sci
Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration
Retina
Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab
Eye
Predicted biological activity of intravitreal VEGF Trap
Br J Ophthalmol
Cited by (45)
Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration
2021, Survey of OphthalmologyRetinal pigment epithelium tears: Classification, pathogenesis, predictors, and management
2017, Survey of OphthalmologyCitation Excerpt :Because aflibercept is 140 times superior to ranibizumab with regard to anti-VEGF binding, they proposed that aflibercept is more potent in CNVM contraction.29 However, Aflibercept, however, is more efficient than ranibizumab and bevacizumab with regard to PED resolution.23,32,90 Although aflibercept increases CNVM contraction, it provides quick reduction in hydrostatic pressure.
Ali Dirani (MD, MPH, MSc) is currently a clinical retina fellow at Jules-Gonin Eye hospital (University of Lausanne, Switzerland). He is an ophthalmologist graduated from Saint-Joseph University (Beirut, Lebanon). He holds a master degree in public health and a master in biological sciences (genetics and biochemistry). He had published many clinical studies and had participated in many international meetings.
Irmela Mantel, MD is currently a medical retina consultant at the Jules Gonin Eye Hospital in Lausanne, Switzerland. She is actively involved in a number of research projects investigating retinal degenerative disorders and in particular age-related macular degeneration. Dr. Mantel received her medical degree from the University of Zurich, Switzerland. After an ophthalmologic residency in Switzerland (Lucerne and Lausanne), she was a medical retina fellow to Professor Alan Bird at Moorfields Eye Hospital in London, England.